Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The facility is spread across 215000 sq. feet and provides super-speciality care
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
US $ 555,000 invested by Wavemaker Partners in pre-seed round
9T Labs provides a cost-competitive solution for manufacturing that will allow structural CFRP parts to replace metals at a much faster rate in demanding applications in many sectors such as aerospace, automotive and healthcare
Subscribe To Our Newsletter & Stay Updated
